Switzerland’s Datwyler to build $102M drug delivery plant in Delaware

Swiss industrial supplier Datwyler Group said it will build a $102 million drug delivery production plant in Maryland that will employ about 120 people.

The facility, which is slated for Middletown, DE, will manufacture high-quality elastomer components for injectable drug delivery systems, the company said. Construction on the project is expected to begin by the end of the year with completion likely in the first half of 2018.

With the addition of the plant, Datwyler  “will be able to significantly boost its position in the world’s largest pharmaceutical market,” the company said in a release.

The Maryland facility will use the company’s newest FirstLine standards that focus on manufacturing high-quality elastomer components by using the latest in clean room technology, automated production cells and fully automated camera inspection.

Datwyler, which has been operating in the U.S. since 1981, says the new plant will help it serve customers in the U.S., Europe and Asia.

In separate news, Datwyler announced last week that it completed its purchase of Germany based Ott, which will give its sealing solutions division more depth in injection moulding with thermoplastics and liquid silicone.

- here’s the release 

Related Articles:
GSK relocates vaccine R&D to Maryland with new global center 
AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.